A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.